FDA Rejects Disc Medicine's Bitopertin for Rare Blood Disorder EPP Despite Commissioner's Priority Voucher on February 17, 2026 Bitopertin CNPV Disc Medicine Erythropoietic Protoporphyria Protoporphyrin IX rejection surrogate endpoint United States Food and Drug Administration +